IDEAYA reports 39% ORR in IDE397 Phase 2 monotherapy for MTAP-deletion cancers

IDEAYA Biosciences, Inc.

Overall response rate 39% (1 CR, 6 PRs by RECIST 1.1) in 18 evaluable MTAP-deletion urothelial cancer and NSCLC patients.
Disease control rate 94%; tumor shrinkage observed in 14/18 evaluable patients; 5 of 7 responses still ongoing.
81% ctDNA molecular response rate (13/16 reportable patients with ≥50% ctDNA reduction).
Favorable safety: 5.6% Grade 3+ drug-related AE (1 asthenia); no drug-related discontinuations.
No FDA-approved therapies for MTAP-deletion solid tumors; IDE397 30 mg QD tablet enables long-term dosing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.